Amrubicin, a novel 9-aminoanthracycline, enhances the antitumor activity of chemotherapeutic agents against human cancer cells in vitro and in vivo

Cancer Science

Volumn 98, Issue 3, 2007, Pages 447-454

  Hanada, Mitsuharu ^a   Noguchi, Toshihiro ^a   Yamaoka, Takashi ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMRUBICIN; AMRUBICINOL; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; DRUG METABOLITE; GEFITINIB; GEMCITABINE; IRINOTECAN; NAVELBINE; TRASTUZUMAB; UFT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EXPOSURE; DRUG POTENTIATION; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT; WEIGHT REDUCTION;

ANIMALS; ANTHRACYCLINES; ANTIBODIES, MONOCLONAL; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CELL LINE, TUMOR; CISPLATIN; DEOXYCYTIDINE; DRUG SYNERGISM; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; QUINAZOLINES; RANDOM ALLOCATION; STOMACH NEOPLASMS; TEGAFUR; URACIL; VINBLASTINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33846683446     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00404.x     Document Type: Article

References (56)

1. Perkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001; 37: S4-66.
2. Noda K, Nishiwaki Y, Kawahara M et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. New Engl J Med 2002; 346: 85-91.
3. Kelly K, Crowley J, Bunn PA Jr. et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group Trial. J Clin Oncol 2001; 19: 3210-18.
4. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. New Engl J Med 2002; 346: 92-8.
5. Ishizumi K, Ohashi N, Tanno N. Stereospecific total synthesis of 9-aminoanthracyclines: (+)-9-amino-9-deoxydaunomycin and related compounds. J Org Chem 1987; 52: 4477-85.
6. Morisada S, Yanagi Y, Noguchi T, Kashiwazaki Y, Fukui M. Antitumor activities of a novel 9-aminoanthracycline (SM-5887) against mouse experimental tumors and human tumor xenografts. Jpn J Cancer Res 1989; 80: 69-76.
7. Suzuki T, Minamide S, Iwasaki T, Yamamoto H, Kanda H. Cardiotoxicity of a new anthracycline derivative (SM-5887) following intravenous administration to rabbits: Comparative study with doxorubicin. Invest New Drugs 1997; 15: 219-25.
8. Hanada M, Mizuno S, Fukushima A, Saito Y, Noguchi T, Yamaoka T. A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex. Jpn J Cancer Res 1998; 89: 1229-38.
9. Yamaoka T, Hanada M, Ichii S, Morisada S, Noguchi T, Yanagi Y. Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells. Jpn J Cancer Res 1998; 89: 1067-73.
10. Noguchi T, Ichii S, Morisada S, Yamaoka T, Yanagi Y. Tumor-selective distribution of an active metabolite of the 9-aminoanthracycline amrubicin. Jpn J Cancer Res 1998; 89: 1061-9.
11. Noguchi T, Ichii S, Morisada S, Yamaoka T, Yanagi Y. In vivo efficacy and tumor-selective metabolism of amrubicin to its active metabolite. Jpn J Cancer Res 1998; 89: 1055-60.
12. Ogawa M. Novel anticancer drugs in Japan. J Cancer Res Clin Oncol 1999; 125: 134-40.
13. Chou T-C, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
14. Inaba M. Experimental treatment protocols. In: Nomura T, Sakurai Y, Inaba M, eds. The Nude Mouse and Anticancer Drug Evaluation. Tokyo: Japanese Journal of Cancer and Chemotherapy Publishers Inc., 1996; 43 -5.
15. Morisada S, Yanagi Y, Kashiwazaki Y, Fukui M. Toxicological aspects of a novel 9-aminoanthracycline, SM-5887. Jpn J Cancer Res 1989; 80: 77-82.
16. Xamboni WC, Gervais AC, Egorin MJ et al. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma. Cancer Chemother Pharmacol 2004; 53: 329-36.
17. Kawato Y, Furuta T, Aonuma M, Yasuoka M, Yokokura T, Matsumoto K. Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice. Cancer Chemother Pharmacol 1991; 28: 192-8.
18. Sun F-X, Tohgo A, Bouvet M et al. Efficacy of camptothecin analog DX-8951f (exatecan mesylate) on human pancreatic cancer in an orthotopic metastatic model. Cancer Res 2003; 63: 80-5.
19. Ashizawa T, Miyoshi K, Asada M et al. Antitumor activity of navelbine (vinorelbine ditartrate), a new vinca alkaloid analog. Jpn J Cancer Chemother 1993; 20: 59-66.
20. Pietras RJ, Pegram MD, Finn RS, Maneval DA, Slamon DJ. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 1998; 17: 2235-49.
21. Yamada T, Yamada Y, Asanuma F, Kawamura E, Suzuki T. Antitumor activity of UFT and docetaxel on human breast carcinoma xenografts. Jpn J Cancer Chemother 2000; 27: 1725-30.
22. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000; 6: 4885-92.
23. Iseki H, Kajimura N, Ohue C, Tanaka R, Akiyama Y, Yamaguchi K. Cytokine production in five tumor cell lines with activity to induce cancer cachexia syndrome in nude mice. Jpn J Cancer Res 1995; 86: 562-7.
24. Naoe Y, Kawamura I, Inami M et al. Anti-cachectic effect of FK317, a novel anti-cancer agent, in colon 26 and LX-1 models in mice. Jpn J Cancer Res 1998; 89: 1318-25.
25. Ohnishi Y, Nakamura H, Yoshimura M et al. Prolonged survival of mice with human gastric cancer treated with an anti-c-ErbB-2 monoclonal antibody. Br J Cancer 1995; 71: 969-73.
26. Oki E, Sakaguchi Y, Toh Y et al. Induction of apoptosis in human tumor xenografts after oral administration of uracil and tegafur to nude mice bearing tumours. Br J Cancer 1998; 78: 625-30.
27. Wakeling AE, Guy SP, Woodburn JR et al. ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002; 62: 5749-54.
28. Yana T, Negoro Y, Takada S, Yokota M, Fukuoka M. Phase II study of amrubicin (SM-5887), a 9-aminoanthracycline, in previously untreated patients with extensive stage small-cell lung cancer (ED-SCLC): A West Japan lung cancer group trial. Proc Am Soc Clin Oncol 1998; 17: 450a.
29. Fukuoka M, Furuse K, Saijo N et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991; 83: 855-61.
30. Sugiura T, Ariyoshi Y, Negoro S et al. Phase I/II study of amrubicin, a novel 9-aminoanthacycline, in patients with advanced non-small-cell lung cancer. Invest New Drugs 2005; 23: 331-7.
31. Sawa T, Yana T, Takada M et al. Multicenter phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer (study 1): West Japan thoracic oncology group (WJTOG) trial. Invest New Drugs 2006; 24: 151-8.
32. Yamauchi S, Kudoh S, Kimura T, Hirata K, Yoshikawa J. Additive effects of amrubicin with cisplatin on human lung cancer cell lines. Osaka City Med J 2002; 48: 69-76.
33. Takigawa N, Takeyama M, Shibayama T et al. The combination effect of amrubicin with cisplatin or irinotecan for small-cell lung cancer cells. Oncol Rep 2006; 15: 837-42.
34. Kondo H, Kanzawa F, Saijo N. Analysis of in vitro combination effects between cisplatin and etoposide against small cell lung cancer cell lines. J Jpn Soc Cancer Ther 1993; 28: 592-601.
35. Ohe Y, Negoro S, Matsui K et al. Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer. Ann Oncol 2005; 16: 430-6.
36. D'Arpa P, Liu LF. Topoisomerase-targeting antitumor drugs. Biochim Biophys Acta 1989; 989: 163-77.
37. Eder JP, Chan V, Wong J et al. Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivo. Cancer Chemother Pharmacol 1998; 42: 327-35.
38. Whitacre CM, Zborowska E, Gordon NH, Mackay W, Berger NA. Topotecan increases topoisomerase IIα levels and sensitivity to treatment with etoposide in schedule-dependent process. Cancer Res 1997; 57: 1425-8.
39. Saijo N. Progress in treatment of small-cell lung cancer; role of CPT-11. Br J Cancer 2003; 89: 2178-83.
40. Negoro S, Masuda N, Takada Y et al. Randomized phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br J Cancer 2003; 88: 335-41.
41. Hotta K, Takigawa N, Kiura K et al. Phase I study of irinotecan and amrubicin in patients with advanced non-small-cell lung cancer. Anticancer Res 2005; 25: 2429-34.
42. Zhang CC, Yang J-M, Bash-Babula J et al. DNA damage increases sensitivity to Vinca alkaloids and decreases sensitivity to taxanes through p53-dependent repression of microtubule-associated protein 4. Cancer Res 1999; 59: 3663-70.
43. Chua S, Smith IE, A'Hern RP et al. Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: Analysis of response and tolerability in randomized phase III trial (TOPIC 2). Ann Oncol 2005; 16: 1435-41.
44. Ejlertsen B, Mouridsen HT, Langkjer ST, Andersen J, Sjöström J, Kjaer M. Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: A Scandinavian breast group trial (SBG9403). J Clin Oncol 2004; 22: 2313-20.
45. Wachters FM, van Putten JWG, Kramer H et al. First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: A phase III trial. Br J Cancer 2003; 89: 1192-9.
46. Illiano A, Battiloro C, Formato R et al. Phase I/II study of gemcitabine and epirubicine in stage IIIB-IV non small cell lung cancer. Frontiers Bioscience 2006; 11: 2349-53.
47. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. New Engl J Med 2001; 344: 783-92.
48. Jarvinen TA, Kononen J, Pelto-Huikko M, Isola J. Expression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer. Am J Pathol 1996; 148: 2073-82.
49. Harris LN, Yang L, Tang C, Yang D, Lupu R. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin β-2. Clin Cancer Res 1998; 4: 1005-12.
50. Harris LN, Yang L, Liotcheva V et al. Induction of topoisomerase II activity after erbB2 activation is associated with a differential response to breast cancer chemotherapy. Clin Cancer Res 2001; 7: 1497-504.
51. Pegram MD, Konecny GE, O'Callagham C, Beryt M, Pietras R, Slamon DJ. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004; 96: 739-49.
52. Crone SA, Zhao Y-Y, Fan L et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nature Med 2002; 8: 459-65.
53. Noda T, Watanabe T, Kohda A, Hosokawa S, Suzuki T. Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs. Invest New Drugs 1998; 16: 121-8.
54. Nakai S, Akao K, Ito M, Kanamaru H, Nakatsuka I. Studies on the metabolic fate of amrubicin hydrochloride (SM-5887), a novel antitumor agent (IV): Metabolism of SM-5887 in rats and dogs. Drug Metab Pharmacokinet 1998; 13: 100-12.
55. Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994; 9: 1829-38.
56. Friedmann B, Caplin M, Hartley JA, Hochhauser D. Modulation of DNA repair in vitro after treatment with chemotherapeutic agents by the epidermal growth factor receptor inhibitor gefitinib (ZD1839). Clin Cancer Res 2004; 10: 6476-86.